+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
C

Actively Recruiting

Researchers are studying an experimental drug called linvoseltamab compared to another drug, daratumumab, in adults with Smoldering Multiple Myeloma SMM who have a high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the progression to multiple myeloma better than daratumumab. The study also looks at side effects, drug levels in the blood, and whether the body makes antibodies against the study drug. Participants are randomly assigned to receive either linvoseltamab or daratumumab, both administered according to the study protocol. The trial follows participants for up to five years to assess clinical and biochemical progression-free survival and other outcomes. Additional measures include response rates, adverse events, quality of life, and antibody presence against linvoseltamab. During the study, participants will undergo regular evaluations including clinical assessments and laboratory tests to monitor disease status, drug levels, and side effects. Quality of life questionnaires and other patient-reported outcomes will be collected over several years. Safety and response will be closely monitored throughout the trial, which may last up to nine years in total for long-term outcomes.

Age: 18Years +All GendersPhase 3
33 locations
I

Actively Recruiting

Psoriatic arthritis PsA is a type of arthritis that causes joint swelling and stiffness, often occurring in people with the skin condition psoriasis. This study aims to understand how long patients continue treatment and how effective risankizumab RZB is compared to other advanced treatments for PsA in everyday clinical settings. The study will take place outside the United States across about 15 countries, involving between 900 and 1200 adult participants. Participants will receive either risankizumab or other biologic disease-modifying antirheumatic drugs bDMARDs as prescribed by their doctors following local guidelines. Treatments will be given as part of regular medical care without additional interventions from the study. Participants will be followed and observed for 24 months during their routine clinical visits. During the study, participants will attend their usual medical appointments where doctors will monitor their treatment persistence and response. The main outcome measured is how many participants continue their prescribed treatment up to 24 months. There is no expected extra burden or additional procedures for participants beyond their standard care.

Age: 18Years - 75YearsAll Genders
132 locations
R

Actively Recruiting

Researchers are studying ways to reduce the duration of immunotherapy treatment in patients with advanced non-small cell lung cancer NSCLC who have their disease controlled after initial treatment. The study focuses on comparing a shorter immunotherapy maintenance period of 6 months to the usual 2 years to see if less treatment can still be effective. This phase II-III randomized study enrolls patients with stage IV NSCLC who have not received prior treatment for advanced disease. Participants will first receive a combination of chemotherapy and pembrolizumab for about 6 months, using specific chemotherapy drugs based on their cancer type. After this induction, patients showing disease control without severe side effects will be randomly assigned to one of two groups continuing pembrolizumab with or without pemetrexed for certain cancer types for up to 2 years or observation with or without pemetrexed. Researchers will monitor various factors including patient characteristics and tumor markers. During the study, participants will attend scheduled visits for treatment and monitoring, including imaging scans to measure tumor response and laboratory tests to check health status. Quality of life and survival will be tracked up to about 24 months after randomization. The study also collects data on side effects and progression-free survival to better understand the benefits and risks of shorter versus longer immunotherapy maintenance.

Age: 18Years - 74YearsAll GendersPhase 2Phase 3
44 locations
C

Actively Recruiting

Ventilator-associated pneumonia VAP is a common hospital-acquired infection in intensive care units linked to longer use of mechanical ventilation and the overuse of antibiotics. This trial evaluates two strategies for starting antibiotic treatment in patients suspected of having non-severe VAP immediate antibiotic therapy after sampling versus waiting for bacteriological confirmation before starting antibiotics. The study aims to understand the impact of these approaches on patient outcomes and antibiotic resistance. Participants are randomly assigned to one of two groups the usual care group, where antibiotics begin within one hour of randomization based on clinical judgment, or the conservative strategy group, where antibiotics are delayed until microbiological results confirm infection. If cultures are negative, antibiotics are stopped or not started. If confirmed, antibiotics targeting the identified bacteria are given for seven days. Treatment decisions consider local protocols and resistance risks. During the study, participants are closely monitored for 28 days to assess survival and duration of mechanical ventilation. Various clinical scores and infection-related outcomes are recorded, including organ failure, infection clearance, antibiotic use, and hospital stay length. The study also evaluates antibiotic resistance and adverse effects. Data are collected from randomization through ICU and hospital discharge, with a primary focus on death or ventilation status at day 28.

Age: 18Years +All GendersPhase Not Applicable
42 locations
C

Actively Recruiting

Researchers are investigating the effects of different target mean arterial pressure MAP levels on neurofunctional outcomes in adults who have experienced out-of-hospital cardiac arrest. This condition often leads to death in intensive care units due to shock or brain damage caused by lack of oxygen. The study aims to compare a standard MAP target of at least 65 mmHg with a higher target of at least 90 mmHg during the first 24 hours after cardiac arrest, as current practices and studies suggest that brain blood flow regulation may require different pressure levels to improve recovery. Participants will be randomly assigned to one of two groups. One group will receive norepinephrine to maintain a high MAP of at least 90 mmHg for 24 hours, then switch to the standard target of 65 mmHg until ICU discharge. The other group will receive norepinephrine to maintain the standard MAP target of at least 65 mmHg for 24 hours, continuing this target until ICU discharge. This approach evaluates whether a higher blood pressure target soon after cardiac arrest improves neurological recovery. During the study, participants will be monitored in the ICU with ongoing assessments including survival status and neurofunctional outcomes up to 180 days after inclusion. Researchers will also observe secondary outcomes such as quality of life, clinical frailty, organ support needs, and kidney function. The study will track these measures through hospital discharge and several months afterward to assess the longer-term effects of the MAP targets on recovery and health.

Age: 18Years +All GendersPhase Not Applicable
31 locations
S

Actively Recruiting

Researchers are investigating the urinary microbiotas role in bladder cancer, a common cancer especially affecting men over 60, with smoking as a known risk factor. The study aims to explore whether certain bacteria or viruses in bladder tissue microbiota contribute to bladder cancer development by comparing microbiota from cancerous and healthy bladder tissues in the same patient. This research builds on earlier findings that showed differences in microbiota biodiversity between cancerous and healthy tissues. Participants will undergo biopsies during a procedure called RTUV, performed under anesthesia via cystoscopy in an operating room. The study uses advanced global metagenomics to analyze the bacterial and viral microbiota biodiversity in bladder tissues. This multicenter study will enroll men over 18 undergoing their first RTUV for suspected bladder cancer with specific clinical signs. During the 36-month study, researchers will assess the diversity of bacterial and viral microbiota in bladder tissues. Participants will provide informed consent, and safety will be ensured by screening for infections and contraindications before biopsy. The main measurement is the bacterial microbiota biodiversity, with viral microbiota diversity as a secondary outcome, helping to better understand bladder cancers microbial environment.

Age: 18Years +MALEPhase Not Applicable
8 locations
S

Actively Recruiting

Stroke is a major health issue affecting over 150,000 patients in France, with ischemic stroke making up 80-85% of cases in western countries. This research focuses on young adults aged 18 to 45 who have been diagnosed with ischemic stroke. The study aims to understand how cognitive functions change over time after stroke, looking at overall brain function and specific areas like memory, attention, and social cognition. It also investigates how brain lesions, especially in white matter, affect recovery. Participants will undergo cerebral MRI scans at 72 hours, 3 months, and 12 months after their stroke to examine brain lesions. The study involves repeated neuropsychological assessments and functional evaluations to track cognitive recovery and impairment over a year. This approach helps detail the extent and progression of cognitive issues following ischemic stroke in young adults. During the study, participants will complete various tests and questionnaires in French to assess cognitive abilities. Researchers will monitor changes in global cognitive efficiency and specific neurocognitive domains between 3 and 12 months after stroke. The study measures how white matter lesions relate to cognitive recovery, with continuous follow-up over one year to evaluate neurocognitive outcomes and related brain imaging findings.

Age: 18Years - 45YearsAll GendersPhase Not Applicable
2 locations
L

Actively Recruiting

This research aims to collect long-term safety and effectiveness information on commercially available Corin hip arthroplasty devices. It focuses on patients who have had hip replacement surgery using Corin implants, including those with primary, secondary, or post-traumatic osteoarthrosis, femur head necrosis, congenital dislocations, and revision surgeries. The study supports post-market surveillance and clinical evaluations of these devices. Participants are patients with hip implants from Corin. The study observes their outcomes over many years, starting during surgery and continuing up to 20 years after. Key evaluations include clinical performance, safety, radiological positioning and bone integration of the implants, as well as patient quality of life and satisfaction at various intervals. During the study, participants will undergo assessments at multiple time points including 3 months, 2.5 years, and up to 20 years after surgery. Researchers will collect data on implant outcomes, patient well-being, and implant safety. The main measure is the long-term outcome at 10 years, with additional follow-ups at 15 and 20 years to monitor ongoing performance and safety. The total duration of participation can extend up to 30 years from the start date.

Age: 18Years +All Genders
13 locations
C

Actively Recruiting

Researchers are collecting biological samples to improve diagnosis and treatment of rare neuroimmune disorders affecting the central and peripheral nervous system. These disorders include Paraneoplastic Neurological Syndromes PNS and Autoimmune Encephalitis AE, which involve immune system activity. The study aims to support faster and more accurate diagnosis, benefiting patients with these conditions by enhancing future treatment approaches. Participants diagnosed with PNS or AE will have biological samples collected once, including blood and possibly cerebrospinal fluid if available. Blood samples will be used to obtain serum, buffy coat, plasma, and peripheral blood mononuclear cells. If cerebrospinal fluid is drawn for diagnosis, any remaining sample will be stored. This collection will occur during a single visit, and samples will be stored for up to 10 years. During the study, participants will provide consent and undergo sample collection only once. Researchers will monitor the blood samples and cerebrospinal fluid biocollection over 10 years. The study emphasizes scientific collaboration and ongoing research to improve understanding and treatment of these neurological disorders. Participation duration focuses on the collection and long-term storage of biological samples.

All AgesAll GendersPhase Not Applicable
62 locations

1-10 of 15

1